AIMS: Hypoxia induces expression of various genes and microRNAs (miRs) that regulate angiogenesis and vascular function. In this study, we investigated a new functional role of new hypoxia-responsive miR-101 in angiogenesis and its underlying mechanism for regulating heme oxygenase-1 (HO-1) and vascular endothelial growth factor (VEGF) expression. RESULTS: We found that hypoxia induced miR-101, which binds to the 3'untranslated region of cullin 3 (Cul3) and stabilizes nuclear factor erythroid-derived 2-related factor 2 (Nrf2) via inhibition of the proteasomal degradation pathway. miR-101 overexpression promoted Nrf2 nuclear accumulation, which was accompanied with increases in HO-1 induction, VEGF expression, and endothelial nitric oxide synthase (eNOS)-derived nitric oxide (NO) production. The elevated NO-induced S-nitrosylation of Kelch-like ECH-associated protein 1 and subsequent induction of Nrf2-dependent HO-1 lead to further elevation of VEGF production via a positive feedback loop between the Nrf2/HO-1 and VEGF/eNOS axes. Moreover, miR-101 promoted angiogenic signals and angiogenesis both in vitro and in vivo, and these events were attenuated by inhibiting the biological activity of HO-1, VEGF, or eNOS. Moreover, these effects were also observed in aortic rings from HO-1(+/-) and eNOS(-/-) mice. Local overexpression of miR-101 improved therapeutic angiogenesis and perfusion recovery in the ischemic mouse hindlimb, whereas antagomiR-101 diminished regional blood flow. INNOVATION: Hypoxia-responsive miR-101 stimulates angiogenesis by activating the HO-1/VEGF/eNOS axis via Cul3 targeting. Thus, miR-101 is a novel angiomir. CONCLUSION: Our results provide new mechanistic insights into a functional role of miR-101 as a potential therapeutic target in angiogenesis and vascular remodeling.
AIMS: Hypoxia induces expression of various genes and microRNAs (miRs) that regulate angiogenesis and vascular function. In this study, we investigated a new functional role of new hypoxia-responsive miR-101 in angiogenesis and its underlying mechanism for regulating heme oxygenase-1 (HO-1) and vascular endothelial growth factor (VEGF) expression. RESULTS: We found that hypoxia induced miR-101, which binds to the 3'untranslated region of cullin 3 (Cul3) and stabilizes nuclear factor erythroid-derived 2-related factor 2 (Nrf2) via inhibition of the proteasomal degradation pathway. miR-101 overexpression promoted Nrf2 nuclear accumulation, which was accompanied with increases in HO-1 induction, VEGF expression, and endothelial nitric oxide synthase (eNOS)-derived nitric oxide (NO) production. The elevated NO-induced S-nitrosylation of Kelch-like ECH-associated protein 1 and subsequent induction of Nrf2-dependent HO-1 lead to further elevation of VEGF production via a positive feedback loop between the Nrf2/HO-1 and VEGF/eNOS axes. Moreover, miR-101 promoted angiogenic signals and angiogenesis both in vitro and in vivo, and these events were attenuated by inhibiting the biological activity of HO-1, VEGF, or eNOS. Moreover, these effects were also observed in aortic rings from HO-1(+/-) and eNOS(-/-) mice. Local overexpression of miR-101 improved therapeutic angiogenesis and perfusion recovery in the ischemicmouse hindlimb, whereas antagomiR-101 diminished regional blood flow. INNOVATION: Hypoxia-responsive miR-101 stimulates angiogenesis by activating the HO-1/VEGF/eNOS axis via Cul3 targeting. Thus, miR-101 is a novel angiomir. CONCLUSION: Our results provide new mechanistic insights into a functional role of miR-101 as a potential therapeutic target in angiogenesis and vascular remodeling.
Authors: Laura Poliseno; Andrea Tuccoli; Laura Mariani; Monica Evangelista; Lorenzo Citti; Keith Woods; Alberto Mercatanti; Scott Hammond; Giuseppe Rainaldi Journal: Blood Date: 2006-07-18 Impact factor: 22.113
Authors: Lisa B Frankel; Jiayu Wen; Michael Lees; Maria Høyer-Hansen; Thomas Farkas; Anders Krogh; Marja Jäättelä; Anders H Lund Journal: EMBO J Date: 2011-09-13 Impact factor: 11.598
Authors: Aikseng Ooi; Karl Dykema; Asif Ansari; David Petillo; John Snider; Richard Kahnoski; John Anema; David Craig; John Carpten; Bin-Tean Teh; Kyle A Furge Journal: Cancer Res Date: 2013-01-30 Impact factor: 12.701
Authors: David Hassel; Paul Cheng; Mark P White; Kathryn N Ivey; Jens Kroll; Hellmut G Augustin; Hugo A Katus; Didier Y R Stainier; Deepak Srivastava Journal: Circ Res Date: 2012-09-05 Impact factor: 17.367
Authors: Francesca Patella; Eleonora Leucci; Monica Evangelista; Brian Parker; Jiayu Wen; Alberto Mercatanti; Milena Rizzo; Elena Chiavacci; Anders H Lund; Giuseppe Rainaldi Journal: J Cell Mol Med Date: 2013-06-26 Impact factor: 5.310
Authors: Lingegowda S Mangala; Hongyu Wang; Dahai Jiang; Sherry Y Wu; Anoma Somasunderam; David E Volk; Ganesh L R Lokesh; Xin Li; Sunila Pradeep; Xianbin Yang; Monika Haemmerle; Cristian Rodriguez-Aguayo; Archana S Nagaraja; Rajesha Rupaimoole; Emine Bayraktar; Recep Bayraktar; Li Li; Takemi Tanaka; Wei Hu; Cristina Ivan; Kshipra M Gharpure; Michael H McGuire; Varatharasa Thiviyanathan; Xinna Zhang; Sourindra N Maiti; Nataliya Bulayeva; Hyun-Jin Choi; Piotr L Dorniak; Laurence Jn Cooper; Kevin P Rosenblatt; Gabriel Lopez-Berestein; David G Gorenstein; Anil K Sood Journal: JCI Insight Date: 2016-10-20
Authors: Chaoqun Huang; Xiao Xiao; Ye Yang; Amorite Mishra; Yurong Liang; Xiangming Zeng; Xiaoyun Yang; Dao Xu; Michael R Blackburn; Craig A Henke; Lin Liu Journal: J Biol Chem Date: 2017-07-18 Impact factor: 5.157
Authors: Cody J Schmidlin; Aryatara Shakya; Matthew Dodson; Eli Chapman; Donna D Zhang Journal: Semin Cancer Biol Date: 2021-05-18 Impact factor: 15.707